Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · November 20, 2023

Efficacy and Safety of Tildrakizumab in Older Patients With Psoriasis

Acta Dermato-Venereologica


Additional Info

Acta Dermato-Venereologica
Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks
Acta Derm Venereol 2023 Oct 25;103(xx)adv17752, ELM Ter Haar, JMPA Van den Reek, K Gaarn Du Jardin, A Barbero-Castillo, EMGJ De Jong, SFK Lubeek

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading